I am passionate about bridging science, strategy, and society through innovation in drug discovery. My expertise lies in DMPK, toxicology, in vivo pharmacology, and drug delivery systems (DDS), supported by about two decades of experience in translational research aimed at accelerating drug discovery and development. Recently, I have expanded my focus to Management of Technology (MOT), innovation strategy, and the societal impact of next-generation therapeutic modalities, particularly proximity-inducing therapeutics and advanced drug delivery technologies. I believe that scientific breakthroughs create their greatest value only when translated into practical medicines that improve patient access and healthcare sustainability. My experience in DMPK has shaped a broader perspective: from understanding drug distribution within the body to considering how therapeutic innovations can be effectively distributed throughout healthcare systems and society. I am also committed to advancing the next generation of scientists through education, technical advising, and collaborative research. By integrating scientific excellence with strategic thinking, I aim to contribute not only to drug discovery but also to the broader innovation ecosystem that enables innovative therapies to reach patients more efficiently. I believe that the ultimate goal of drug discovery is not to advance a specific modality, but to deliver effective and accessible medicines to as many patients as possible. これまで約20年間、創薬研究の現場においてDMPK（薬物動態）を中核に据え、薬理、そしてDDS（ドラッグデリバリーシステム）にいたるまで、幅広い領域に深く関わってきました。 近年は、PROTACをはじめとする最先端のモダリティ研究に注力する一方で、技術経営（MOT）の視点も取り入れ、「優れたサイエンスを、いかにして現実の医薬品として社会に実装するか」という戦略的なアプローチにも挑戦しています。 新しい技術やトレンドを追うことも大切ですが、一番の原点は「患者さんが本当に必要とする、アクセスの良い薬を届けること」です。これまでに培った現場の経験を活かし、次世代の育成や技術アドバイスを通じて、日本の創薬エコシステム全体の発展に地道に貢献していきたいと考えています。